Pregnant Women With IBD Are More Likely to be Adherent to Biologic Therapies Than Other Medications

Sangmin Lee; Cynthia H. Seow; Kamala Adhikari; Amy Metcalfe


Aliment Pharmacol Ther. 2020;51(5):544-552. 

In This Article


Our population-based retrospective cohort study determined approximately a quarter of women with IBD, who were previously adherent to their maintenance IBD medications 1 year prior to pregnancy, discontinued or were not adherent to their medications during pregnancy. Additionally, we have shown that infants born to women with IBD who were adherent to their maintenance medication were more likely to be admitted into the neonatal intensive care unit than the general obstetric population and similarly for those women who were not adherent to their maintenance IBD medication, although not statistically significant. Medication non-adherence is potentially an important modifiable risk factor to improve pregnancy outcomes in this high-risk pregnancy cohort. Maternal education prior to and during pregnancy influences a woman's perception regarding the risks and benefits of medication use during pregnancy and thus, their adherence to medical therapy. Variability in antenatal care and counselling may be a factor in the differing medication adherence rates. Future studies should investigate whether different models of care or care providers during pregnancy may influence neonatal outcomes through changes in the medication adherence patterns in women with IBD.